ODE V director
This article was originally published in The Tan Sheet
Executive Summary
Robert DeLap, MD/PhD, becomes FDA Office of Drug Evaluation V director starting July 5, following the planned departure of Michael Weintraub, MD, on July 3. FDA announced DeLap's appointment as acting director of the division at the beginning of June ("The Tan Sheet" June 8, p. 1). DeLap had been named deputy director of ODE V a few days before. Previously, he was director of the Division of Oncology Drug Products. Weintraub has not announced his post-FDA plans...